GLG LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

GLG LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,568	Closed	-$310K	–	513
2016 Q3	$310K	Sell	4,568 -703	-13%	-$49.6K	0.02%	471
2016 Q2	$292K	Sell	5,271 -2,166	-29%	-$136K	0.02%	438
2016 Q1	$467K	Sell	7,437 -984	-12%	-$65.4K	0.03%	448
2015 Q4	$793K	Sell	8,421 -14,042	-63%	-$1.3M	0.05%	351
2015 Q3	$1.8M	Buy	+22,463	New	+$2.5M	0.05%	322

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GLG LLC's ALNY Position: Q4 2016 in Review

GLG LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 4,568 shares — an estimated $310K sold.

GLG LLC first reported a position in ALNY in Q3 2015 and held it in 5 quarters. The position peaked at $1.8M in Q3 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

GLG LLC reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
GLG LLC sold 4,568 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $310K.
GLG LLC first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 5 quarters.
GLG LLC's Alnylam Pharmaceuticals position peaked at $1.8M in Q3 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on GLG LLC's 13F filing for Q4 2016, filed 14 Feb 2017.